We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium
Product News

Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium

Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium
Product News

Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Irvine Scientific Introduces PRIME-XV® T Cell Culture Medium"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Irvine Scientific has announced the introduction of PRIME-XV® T Cell Expansion XSFM, a xeno-free and serum-free medium. PRIME-XV T Cell Expansion XSFM is a medium optimized for the expansion of human T cells that reliably maintains potency and is the newest medium in the PRIME-XV cell therapy product line that supports immunotherapy.

Immunotherapy has emerged as a viable approach for treating some forms of cancer. Using a process called adoptive cell transfer (ACT), T cells have been engineered to produce chimeric antigen receptors (CARs), a surface receptor that allows T cells to recognize tumor-specific proteins and subsequently kill the targeted tumor cells.

This method has generated positive results in small clinical trials, indicating its potential as a treatment. To further support the research and development into ACT, efficient expansion of desired T cell subsets with proper potency is critical to ensure an adequate population of T cells with targeted specificity.

“Immunotherapy offers significant hope, particularly in the area of novel cancer treatment options,” said Dr. Jessie H.-T. Ni, Chief Scientific Officer at Irvine Scientific. “We have developed this new medium using the most up-to-date knowledge of T cell biology to deliver improved performance over serum-containing and other existing commercial xeno-free, serum-free media in supporting ex vivo quality expansion of various human T cell subsets.”

Irvine Scientific supports immunotherapy with products and services for cancer stem/initiating cell expansion and tumorsphere formation, mesenchymal stem/stromal cell expansion, and a full suite of recombinant human growth factors to supplement any variety of applications. To facilitate clinical applications and scale-up, PRIME-XV T Cell Expansion XSFM is available for custom formulation and packaging.

Advertisement